Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug works best for shock? major trial to settle debate

NCT ID NCT07562932

Disease control Sponsor: Chonnam National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will compare norepinephrine and dopamine as the first drug given to adults with cardiogenic shock, a life-threatening condition where the heart can't pump enough blood. About 512 participants will be randomly assigned to one of the two drugs. The goal is to see which drug reduces the risk of death or worsening shock within the first month, and causes fewer complications like dangerous heart rhythms or need for a heart pump.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
norepinephrine and dopamine (vasopressor drugs)
What this could lead to
If this trial succeeds, it could show which drug is safer and more effective for stabilizing blood pressure and improving survival in cardiogenic shock.
What could go wrong
This is an early-stage comparison trial; results may not apply to all patients. Both drugs have known risks like arrhythmias, and the study is not yet recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 512 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\&2 1. Age ≥ 19 2. Cardiogenic shocka in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D * Cardiogenic shock was defined as follows, and should fulfill both 1) and 2) 1. systolic blood pressure \<90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure \>90 mm Hg And 2. Impaired cardiac function confirmed by cardiac catheterization or echocardiography * Patients will be further classified based on the SCAI shock classification system as follows: 1. SCAI B: no signs of hypoperfusion 2. SCAI C: any signs of hypoperfusion, cardiogenic shock will be classified as SCAI C, and these include mental status change, cool and clammy skin, mottled skin appearance, decreased urine output (30ml/hour) or lactate over 2.0mmol/L 3. SCAI D: requirement of second-line vasoactive drug or mechanical circulatory support based on the predefined treatment protocol Exclusion Criteria: any of these, 1. Administration of vasoactive drug more than 6 hours before enrollment 2. Patients already on temporary mechanical circulatory supportb before enrollment 3. Glasgow Coma Scale lower than 8 or other evidence of irreversible brain injury 4. Shock etiologies other than cardiogenic which include postcardiotomy shock or mixed shock 5. Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiogenic shock Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chonnam National University Hospital

    Gwangju, 61469, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.